Skip to main content
Damya Laoui

Prof. Dr. ir. Damya LAOUI

ACADEMIC STAFF
+32-2-6291978

Biography

The mission of the Laoui groupĀ is to constantly improve our understanding of the immune compartment in tumors to develop novel cancer therapies against tumor progression, tumor relapse and metastasis. More specifically, the heterogeneity of myeloid cells, focusing in particular on tumor-derived conventional dendritic cells (cDCS), is used as a target for therapeutic intervention. Our research has enabled us to uncover the genetic, phenotypic and functional characteristics of immune cell subpopulations in different activation states in the tumor microenvironment. Indeed, pioneering research published in Nature Communications, has identified and characterized different cDC subsets in the tumor and proven their utility as novel cell-based cancer therapy. In addition, several projects are ongoing in the lab focusing on further improving cDC therapy, bringing it to the clinic as well as increasing the fundamental understanding of their activity and their relation to other cell types within the tumor microenvironment. These projects allowed to build and expand our expertise on both on in vivo orthotopic cancer models for breast cancer, lung cancer and ovarian cancer, analysis techniques such as scRNA-seq, CITE-seq, advanced flow cytometric analysis and Resolve spatial transcriptomics as well as functional ex-vivo and in vitro assays.

Location

Room E8.08
Vrije Universiteit Brussel
Pleinlaan 2
1050 Brussels

Publications

Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1<sup>+</sup> T lymphocyte niches through a feed-forward loop

24/11/2022

Cancer Cell. 2022 Nov 21:S1535-6108(22)00549-9. doi: 10.1016/j.ccell.2022.11.002. Online ahead of print.

NO ABSTRACT

PMID: 36423635 | DOI: 10.1016/j.ccell.2022.11.002

Dendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer

26/08/2022

Cancers (Basel). 2022 Aug 21;14(16):4037. doi: 10.3390/cancers14164037.

NO ABSTRACT

PMID: 36011029 | PMC: PMC9406463 | DOI: 10.3390/cancers14164037

Efficacy of CD40 Agonists Is Mediated by Distinct cDC Subsets and Subverted by Suppressive Macrophages

18/08/2022

Cancer Res. 2022 Oct 17;82(20):3785-3801. doi: 10.1158/0008-5472.CAN-22-0094.

NO ABSTRACT

PMID: 35979635 | DOI: 10.1158/0008-5472.CAN-22-0094

Heterogeneity and function of macrophages in the breast during homeostasis and cancer

24/04/2022

Int Rev Cell Mol Biol. 2022;367:149-182. doi: 10.1016/bs.ircmb.2022.01.002. Epub 2022 Feb 28.

NO ABSTRACT

PMID: 35461657 | DOI: 10.1016/bs.ircmb.2022.01.002

Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions

21/01/2022

Int J Mol Sci. 2022 Jan 14;23(2):904. doi: 10.3390/ijms23020904.

NO ABSTRACT

PMID: 35055096 | PMC: PMC8778019 | DOI: 10.3390/ijms23020904